Cellular-level analyses of SCN5A mutations in left ventricular noncompaction cardiomyopathy suggest...

Area of Science:

• Cardiology
• Genetics
• Electrophysiology

Background:

• Left ventricular noncompaction cardiomyopathy (LVNC) is a serious heart condition linked to arrhythmias and heart failure.
• Genetic factors are increasingly recognized as contributors to cardiovascular diseases like LVNC.

Purpose of the Study:

• To investigate the role of SCN5A variants in LVNC.
• To understand the electrophysiological mechanisms underlying arrhythmia susceptibility in LVNC patients with SCN5A variants.

Main Methods:

• Exome sequencing of LVNC patient myocardial samples.
• Functional evaluation of SCN5A variants in CHO-K1 cells and human embryonic stem cell-derived cardiomyocytes (hESC-CMs) using patch-clamp and microelectrode array (MEA).
• Assessment of antiarrhythmic drug effects, specifically Lidocaine.

Main Results:

• Approximately 50% of LVNC patients carried SCN5A variants associated with ventricular tachycardia.
• SCN5A variants demonstrated gain-of-function properties, increasing channel activation and inactivation.
• SCN5A variants enhanced cardiomyocyte excitability, contractility, and induced fibrillation-like arrhythmias.
• Lidocaine effectively mitigated arrhythmias in the developed models.

Conclusions:

• SCN5A variants are implicated in the arrhythmia susceptibility observed in LVNC patients.
• SCN5A variants contribute to the pathophysiology of LVNC through altered ion channel function.
• SCN5A variant cardiomyocyte models offer a platform for precise arrhythmia therapy development and drug screening.